acucela inc. fy2015 q3 analyst meeting · 2016. 12. 1. · company overview acucela inc. [ticker:...
TRANSCRIPT
Acucela is a clinical-stage biotechnology
company that specializes in discovering and
developing novel therapeutics to treat and
slow the progression of sight-threatening
ophthalmic diseases affecting millions of
individuals worldwide.
Acucela Inc.
FY2015 Q3 Analyst Meeting
Tokyo
November 24, 2015
DISCLAIMER
This presentation contains forward-looking statements concerning our product development, our
technology, our competitors, our intellectual property, our financial condition and our plans for research and
development programs that involve risks, uncertainties and assumptions. These statements are based on
the current estimates and assumptions of the management of Acucela as of the date of this presentation and
are subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place
undue reliance upon these forward-looking statements. Such forward-looking statements are subject to
risks, uncertainties, assumptions and other factors that may cause the actual results of Acucela to be
materially different from those reflected in such forward-looking statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-
looking statements include, among others, those set forth in our reports on file with the Tokyo Securities
Exchange and the United States Securities and Exchange Commission. The Company does not undertake
any obligation to release publicly any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements
contained in this presentation are made only as of the date of this presentation.
Acucela Inc. [ticker: 4589] 2
Corporate Overview
Company Overview
Acucela Inc. [ticker: 4589] 4
An ophthalmology-focused, science-driven company
People and Strategy• Executive leadership with experience in health care
management, life science administration and technology
• Broad-skilled employee base in research, development and
operations
• Strategic plan to develop an innovative portfolio of
ophthalmology products
Partnership• Long-time partnership with Otsuka Pharmaceutical
• Potential high-reward alliance
• Acucela has rights for lead investigational candidate
(Emixustat) in Europe, South and Central America and most
of Africa
Technology• Unique mechanism of action in visual cycle modulation (VCM)
• Lead clinical trial program in geographic atrophy (GA)
associated with dry age-related macular degeneration (AMD);
no treatments currently available
• 110 granted patents; 175 pending patents (as of 11/10/15)
Financials• Successful 2014 IPO; $163M (gross) raised
• Cash, short-term and long-term investments for the three
months ended 9/30/15 was $166M ready to invest in
ongoing programs, business development and internal
research and development
FYE2015 Q3 Highlights
Recent Highlights
Acucela Inc. [ticker: 4589] 6
Date Highlights
Jul 2 Acucela Hires Roger Girard as Chief Strategy Officer
Aug 5 Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine
Aug 25 Acucela Hires Dr. George Lasezkay as Executive Vice President of Legal Affairs
Nov 4 Acucela Validates Sampling Method That Could Pave Way for More Efficient Clinical Tests
Management Team
Acucela Inc. [ticker: 4589] 7
An experienced management team driving current and future
pipeline development, including device, pharma & biotech assets
George Lasezkay, PharmD, JD
EVP General Counsel
Allergan, Inc.
RetroSense Therapeutics,
Amakem Therapeutics NV,
Novagali Pharma, SA
Neurotech Pharmaceuticals, Inc.
Acuity Pharmaceuticals,
ISTA Pharmaceuticals, Inc.
Lukas Scheibler, PhD
EVP R&D
Alcon
Novartis PharmaceuticalsJohn Gebhart
Chief Financial OfficerQliance Medical Management Consultant to Remote
Medical International, Ventripoint, and others
Ted Danse, MBA
Chief Business Officer
Neurotech Pharmaceuticals, Inc.
ISTA Pharmaceuticals Inc., Allergan,
Inc., Coopervision, Bausch & Lomb ,
Schering-Plough
Roger Girard
Chief Strategy Officer
Xecutive Advisory Partners LLC
Terra Vista Software
CareCap, Bellevue,
Neuro-ID, IsoRay Medical
Ryo Kubota, MD, PhD
Chairman, President and CEO
Board of Directors
Directors Background
Ryo Kubota, MD PhD Chairman, President and Chief Executive Officer and also founder of Acucela Inc.
Shintaro AsakoChief Executive Officer - DeNA West
Previously, Chief Financial Officer - MediciNova, Inc.
Shiro Mita, PhDPresident and Chief Executive Officer - M’s Science Corporation
Previously: Executive Director of Drug Discovery, Director - Santen Pharmaceuticals Co., Ltd
Eisaku Nakamura
Director - Koinobori Associates Inc.
Previously: Director and General Manager - Bio Sight Capital Co., Ltd , Chief Executive Officer and
President - Berevno Corporation, Board of Directors - CanBas Corporation and Activus Pharma Co. Ltd.
Robert Takeuchi
President - RT Consulting, Inc.
Previously: President - SOFTBANK Finance, America Corporation, Director of International Equity Sales -
Credit Suisse First Boston, Board of Directors SBI Investment Co., Ltd. and Quark Pharmaceuticals, Inc.
Acucela Inc. [ticker: 4589] 8
Corporate Strategy
Treating Sight-Threatening Diseases
Vision R&D
Alliance
&In-
licensing
New
business
Current
pipeline
• Expanding internal
research
capabilities
• Emixustat and OPA-6566
• Optimizing asset
value
• Seeking innovative
approaches to treat
sight-threatening
diseases
Acucela Inc. [ticker: 4589] 10
FY2015 and Beyond
Acucela Inc. [ticker: 4589] 11
Continuous development of the current pipeline and increase in
business development activities to expand the portfolio
Current
Pipeline
Emixustat for GA associated with dry AMD
− 75% of enrolled patients have completed dosing in the Phase 2b/3 trial as of
October 2015
− No safety issues have been identified to date
− Obtained feedback from European regulatory agencies regarding registration
pathway for Emixustat in Europe
Emixustat for Additional Indications
− Evaluating the potential to develop Emixustat for additional indications including
diabetic retinopathy and/or Stargardt’s diseaseNew Business− Expanding internal research capabilities
Alliance &
In-licensing− Pursuing partnering and in-licensing opportunities focused on innovative ophthalmic
technologies
Organization− Hired Executive Vice President of Research and Development
− Hired Chief Business Officer
Partnership with Otsuka Pharmaceutical
Acucela Inc. [ticker: 4589] 12
Investigational Product
CandidatePotential Indication License Territory Financial Terms
Emixustat hydrochloride
(developed by Acucela)
Dry AMD and other
ophthalmic indications
Joint (50/50) - North America
Acucela - Europe, South and
Central America and most of
Africa
Otsuka – Asia-Pacific, some
countries in Africa/Middle East
• Otsuka paid $5M cash upfront payment to
Acucela
• Potential milestone payments: $258M total
• Currently Otsuka and Acucela are equally
sharing all development expenses; Otsuka
loans funds to Acucela for the payment of
Acucela’s share of the development expenses
through to product launch
OPA-6566
(developed by Otsuka)
Glaucoma and other
ophthalmic indications
United States • Currently evaluating next steps for the
program
Unchanged stable relationship with Otsuka Pharmaceutical
FY2015 Q3 Financial Summary
Overview of FY2015 Q3: P/L
FY2014Q3 FY2015Q3 FY2014Q3 FY2015Q3 Reasons for change
P/L Statement USD USD JPY JPY
Revenues from collaboration 27,751 21,524 3,329,010 2,582,019 Decrease due to fewer clinical activities related to Emixustat in 2015.
Expenses
R&D 19,974 17,764 2,396,081 2,130,969
Emixustat 19,191 16,569 2,302,196 1,987,619Decrease due to fewer clinical activities related to Emixustat clinical
trials.
In-licensed(1) 23 4 2,758 426
Internal research(2) 760 1,191 91,127 142,924
Increase in internal research activities and increase related to
severance and retention bonus payments s directly involved in
clinical operations and research.
General and administrative 7,272 21,772 872,349 2,611,770
General and administrative 7,272 10,272 872,349 1,242,270
$1.0M for implementation of new general ledger system, audit
services and equity compliance, new ERP system and others
including hiring of short-term contractors
May 1st Special Shareholder
Meeting and management
change
11,500 1,369,500
Severance cost (cash and stock compensation) of $7.7M, legal and
consulting fees of 1$.5M and others including retention costs and
executive hiring costs
Income (loss) from operations 505 (18,012) 60,580 (2,160,720)
Net income (1,411) (17,228) (169,263) (2,066,671)(1) In-Licensed: includes Rebamipide (program under the terminated Rebamipide Agreement) and OPA-6566 (program under the Glaucoma Agreement)
(2) Internal Research: includes costs and expenses associated with our discovery research activities related primarily to our VCM compounds
Note: 1 USD = 119.96 JPY as of September 30, 2015
Acucela Inc. [ticker: 4589] 14
(US$ and JP¥ in thousands)
Overview of FY2015 Q3: Cash Flow
FY2014Q3 FY2015Q3 FY2014Q3 FY2015Q3 Reasons for change
Cash flow Statement USD USD JPY JPY
Cash flows from operating activities 11,016 (18,609) 1,321,465 (2,232,315)
Cash outflow was primarily the result of a net loss of $17.2M
(¥2.1B), and a decrease in deferred revenue from
collaborations of $6.2M(¥747.5M).
Cash flows from investing activities (124,066) 9,138 (14,882,942) 1,096,152Changes were primarily the result of net purchases of
marketable securities.
Cash flows from financing activities 148,317 (1,140) 17,792,106 (136,755)Net cash used primarily for repurchase of restricted stock
units for employee tax withholdings.
Cash, cash equivalents and short and
long-term investments - end of period187,819 165,545 22,530,765 19,858,754
• Cash from operations and our existing cash and investment balances will be sufficient to fund our ongoing operating activities,
working capital, capital expenditures and other capital requirements for at least the next 12 months
• Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our resea rch and
development activities, the timing and extent of our elections to co -promote product candidates under our collaboration agreements
with Otsuka, and the timing of achievement of milestones under our collaboration agreements with Otsuka
Acucela Inc. [ticker: 4589] 15
Note: 1 USD = 119.96 JPY as of September 30, 2015
(US$ and JP¥ in thousands)
Overview of FY2015 Q3: Balance Sheet
Acucela Inc. [ticker: 4589] 16
Note: 1 USD = 119.96 JPY as of September 30, 2015
12/31/2014 9/30/2015 12/31/2014 9/30/2015 Reasons for change
Balance sheet statement USD USD JPY JPY
Current Assets 111,714 122,379 13,401,208 14,680,562
Cash, cash equivalents and short-
term investments103,786 108,342 12,450,167 12,996,683
Non-current Assets 85,252 58,455 10,226,829 7,012,261
Long-term investments 84,033 57,203 10,080,598 6,862,071
Total Assets 196,966 180,834 23,628,037 21,692,823
Current Liabilities 12,556 7,150 1,506,214 857,690
Long-term Liabilities 47 1,140 5,638 136,755Increase due to long-term deferred rent, lease
incentives and others
Shareholders‘ Equity 184,363 172,544 22,116,185 20,698,378
(US$ and JP¥ in thousands)
4,528 3,869 7,033 6,994
(188)
(21,952)(24,377)
(30,000)
(25,000)
(20,000)
(15,000)
(10,000)
(5,000)
-
5,000
10,000
FY10 FY11 FY12 FY13 FY14 FY15 Est
Operating Profit (Loss)
Financial Overview
Acucela Inc. [ticker: 4589] 17
(USD in thousands)
May 1st Special Shareholder Meeting and management change
34,809 41,495 47,024 54,048
196,966 180,834
-
50,000
100,000
150,000
200,000
250,000
FY10 FY11 FY12 FY13 FY14 FY15Q3
Total Assets
14,101 20,840 25,607 31,124
184,363 172,544
-
50,000
100,000
150,000
200,000
FY10 FY11 FY12 FY13 FY14 FY15Q3
Total Shareholder's Equity
36,457 34,226
46,424
52,947
35,396
23,000 25,500
-
10,000
20,000
30,000
40,000
50,000
60,000
FY10 FY11 FY12 FY13 FY14 FY15 Est
Revenues from Collaboration
IR Activities
Recent and Planned IR Activities
Acucela Inc. [ticker: 4589] 19
1 Total of 375 investors answered the questionnaire: 174 investors said they would consider purchasing and 27 said they will increase or purchase shares
Date IR Activities
Aug 26 FY2015Q2 Analyst Meeting (Large Meeting)
Aug 28-29
Nikkei IR Fair
• 54% investors made a positive response in purchasing or increasing
holdings of Acucela shares1
Aug 28Retail IR Website Update
• http://ir.acucela.jp/story/index.html
Oct 13-15NYC & Boston Non-deal Roadshow
• Met with Bio-tech focused foreign investors
Oct 23Issued article, “Hopes for saving patients who have sight threatening
diseases with an oral indication” on Japanese Investor
Nov 17London Non-deal Roadshow
• Met with Bio-tech focused foreign investors
Nov 18 Jefferies Healthcare Conference (London)
Nov 19 Barclays Japan Corporate Day (London)
Nov 24 FY2015Q3 Analyst Meeting (Small Meeting)
Dec 3 SBI Securities hosted “Internet-based Presentation for Retail Investors”
Dec 14 Ad in the Kaisha Jyoho (Investor Handbook) Vol 87. Japanese Investor Article – available on our website
2015 Nikkei IR Fair – Acucela Booth
Appendix
The Visual Cycle
The visual cycle is a biological process in which dietary vitamin A is converted to a light -sensitive
compound. This process takes place in a specialized tissue called the retinal pigment epithelium (RPE).
During exposure to bright light, the visual cycle is extremely active and can produce toxic by -products of
vitamin A that cannot be eliminated.
Acucela Inc. [ticker: 4589] 21
Retinal Pigment Epithelium
11-cis-retinal
11-cis-retinol
all-trans-retinyl ester
all-trans-retinol
Rod Photoreceptor
11-cis-retinal + Opsin
(Rhodopsin)
RPE65
all-trans retinal
Precursors
of vitamin A
toxins
• In the mammalian visual cycle, the Retinal Pigment Epithelium protein 65 (RPE65) plays a crucial role in the
conversion of dietary vitamin A to visual chromophore, 11-cis retinal.
• The visual chromophore combines with opsin in rod photoreceptors to form rhodopsin.
• Light activation of rhodopsin triggers an electro-chemical cascade which results in visual sensation.
• 11-cis retinal and the product of light-activated rhodopsin (all-trans retinal) have the potential to spontaneously
react with membrane lipids and form vitamin A toxins, such as A2E.
all-trans retinol
Emixustat
Acucela Inc. [ticker: 4589] 22
Formation of Vitamin A Toxins in the Visual Cycle
Visual Cycle Modulation Technology
Visual Cycle Modulation is the use of non-retinoid, small molecule compounds which target
specific proteins of the visual cycle. The intended effect of VCM compounds is to reduce retinal
toxins and preserve the integrity of retinal tissue. Acucela has established a leadership position
in this area as a result of our pioneering efforts to research, discover and develop proprietary
VCM compounds.
Emixustat
Acucela Inc. [ticker: 4589] 23
Emixustat
Hydrochloride
Emixustat Overview:
Lead Investigational Product Candidate
• Non-retinoid small molecule
• Oral administration
• Designed to modulate visual cycle
activity and reduce the accumulation of
toxins in the retina
• Targets a key rate-limiting enzyme of
the visual cycle
• Measureable pharmacologic effect in
the retina through ERG
(Electroretinography or ERG is an eye
test used to detect abnormal function of
the retina - the light-detecting portion of
the eye)
Acucela Inc. [ticker: 4589] 24
Emixustat
Hydrochloride
Drug Development Path Emixustat for GA associated with dry AMD:
Investigational compound based on Acucela’s proprietary VCM
2005 2007 2009 2012 2013
» Phase 2b/3 clinical trial commences
» Two-year treatment
» Toxicology
» Proof-of-concept in
preclinical model
» Medicinal chemistry
» Five phase 1 clinical trials completed
» One phase 2a clinical trial completed
(GA subjects)
» 179 total subjects exposed to Emixustat
» Fast track designation granted
» IND filed
» First human trial
2008
25
2014
» Phase 2b/3 clinical
trial enrollment
completed in 508
subjects
2016
» Phase 2b/3 clinical
trial top line results
expected
Acucela Inc. [ticker: 4589] 25
500
400
300
200
100
dark control
outer
nuclear
layer
Emixustat
(1 mg/kg),
single dose
pre-treatment
p 0.01
Protection from light damage
in mouse model
+8K lux light &
1mg/kg Emixustat
Preclinical Data (ERG following single dose)
Modified From: Bavik C, Henry SH, Zhang Y, Mitts K, McGinn T, Budzynski E, et al. (2015) Visual Cycle Modulation as
an Approach toward Preservation of Retinal Integrity. PLoS ONE 10(5): e0124940. doi:10.1371/journal.pone.0124940
Post-bleach time (min)
10 30 5040200
B-w
ave
ampl
itude
(µ
V)
Vehicle
Emixustat
Treatment:
0.1 mg/kg
0.3 mg/kg
1.0 mg/kg
3.0 mg/kg
Protects Outer Nuclear Layer with Dose
Dependent Reduction in Rod Activity
Acucela Inc. [ticker: 4589] 2626
p 0.01
p 0.001
p 0.001
+8K lux light
30
25
20
15
10
5
Attenuation of A2E Accumulation in abca4-/-
Mice Treated 3 Months with Emixustat
Reduction of
A2E/lipofuscin
Emixustat
(3 mg/kg),
3-month
treatment
abca4-/-
abca4-/-
wild-type
Emixustat (mg/kg)
A2E
(pm
ole/
eye)
Modified From: Bavik C, Henry SH, Zhang Y, Mitts K, McGinn T, Budzynski E, et al. (2015) Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS ONE 10(5): e0124940.
doi:10.1371/journal.pone.0124940
Veh. 0.03 0.1 0.3 1.0 3.0
Day 180Day 0
*
*
*
Acucela Inc. [ticker: 4589] 2727
Emixustat Decreases Retinal Neovascularization in
Dose-dependent Fashion in the Oxygen-Induced
Retinopathy (OIR) Model
40
30
20
10
% N
eova
scul
ariz
atio
n
TreatmentED50 = 0.46 mg/kg
*
**
Modified From: Bavik C, Henry SH, Zhang Y, Mitts K, McGinn T, Budzynski E, et al. (2015) Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS ONE 10(5): e0124940.
doi:10.1371/journal.pone.0124940
75% O2 + Emixustat
75% O2 + vehicle
Air
A
B
C
A
B
C
Acucela Inc. [ticker: 4589] 2828
Emixustat Clinical Data:
Mean Oral PK Profiles
• Single-ascending dose; Phase 1
trial in healthy subjects
• AUC increased approximately
proportionally with dose
• Maximal plasma concentration
(Cmax) also increased linearly with
dose
• Emixustat was readily absorbed
from the GI tract
Acucela Inc. [ticker: 4589] 29
20
15
10
5
Time (h)
4 12 24201680
Mea
n P
lasm
a C
once
ntra
tion
(ng/
ml)
2mg/subject
7mg/subject
10mg/subject
20mg/subject
20mg/subject (cohort 4)
40mg/subject
60mg/subject
75mg/subject
Source: Kubota R, Al-Fayoumi S, Mallikaarjun S, Patil S, Bavik C, Chandler JW. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina. 2014
Mar;34(3):603-9
• Design
− Multi-center, randomized, double-masked, placebo-controlled, dose-escalation study of
the safety, tolerability, pharmacokinetics and pharmacodynamics of emixustat
– A total of 72 patients with geographic atrophy (GA) associated with dry AMD
– Completed in October 2012
• Primary objectives
− Assess the safety and tolerability of different dose levels of emixustat when administered
orally once daily for three months
− Explore the relationship of biologic activity of emixustat using ERG as biomarker
• Summary of Results
− Emixustat was generally safe and well-tolerated
− ERG data confirmed dose-dependent pharmacologic activity in the retina
− Data were published in the June 2015 edition of RETINA: The Journal of Retinal and
Vitreous Diseases
Acucela Inc. [ticker: 4589] 30
Phase 2a Dose Escalation Study
Minutes After Bleach
200
150
100
50
20 3010
Nor
mal
ized
ER
G R
ecov
ery
Prolonged Rod Visual Cycle Suppression with
Emixustat in Patients with GA (at Day 14)
31
Placebo (N=18)
2mg (N=12)
5mg (N=11)
7mg (N=11)
10mg (N=5)
DoseSuppression at
Minute 30
Placebo 2% ± 35%
2 mg 35% ± 42%
5 mg 54% ± 40%
7 mg 62% ± 35%
10 mg 85% ± 14%
Source: Dugel P, Novack R, Csaky K, Richmond P, Birch D, Kubota R. Phase II, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular
degeneration. Retina. June 2015; 35(6): 1173–1183
31Acucela Inc. [ticker: 4589]
• Administration of emixustat to GA
subjects resulted in a dose-dependent
suppression of mean ERG b-wave rod
recovery
• Mean ERG response functions at Days
14, 30 and 60 were comparable,
indicating steady-state inhibition of ERG
responses was achieved by Day 14
• Within 7 to 14 days after the last dose of
emixustat mean ERG b-wave responses
recovered approximately to baseline
-0.05
0
0.05
0.1
0.15
0.2
0.25
Emixustat Clinical: change in GA lesion area at day 90 in Phase 2a dose escalation GA
32Acucela Inc. [ticker: 4589]
Mea
n c
han
ge
in le
sio
n a
rea
fro
m b
asel
ine
to
mo
nth
3 (
mm
2 )
Pooled Emixustat Placebo
N = 23 N = 8
Numerical
difference of
0.23 mm2,
p 0.05
Pooled data from all Emixustat treated patients vs. placebo
for change in lesion area from baseline to month 3 (FAF)
Full Analysis Population – Acucela data on file
Source: Dugel P, Novack R, Csaky K, Richmond P, Birch D, Kubota R. Phase II, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular
degeneration. Retina. June 2015; 35(6): 1173–1183
Phase 2b/3 “SEATTLE” Study
• Design
− Two year, randomized, double-masked, dose-ranging study comparing safety and efficacy of
emixustat with placebo in patients with GA associated with dry AMD
− A total of 508 patients with GA associated with dry AMD were enrolled
• Objectives
− Primary: Determine if emixustat reduces lesion growth rate compared to placebo
− Secondary:
– Evaluate safety and tolerability
– Assess changes in best-corrected visual acuity
– Evaluate the effect on development of wet AMD
− Top-line 2-year trial results anticipated in mid-2016
Acucela Inc. [ticker: 4589] 33
Acucela’s Intellectual Property Position
Update in VCM and Emixustat
(Nov 10, 2015)
Emixustat related
patents
VCM related
patents
Other
patents
Total
patents
Region US Non-US US Non-US
Granted patents 3 15 16 49 27 110
Pending patents 4 52 11 107 1 175
Expiry year 2029 2028-2033 2028-2034 2028-2034
Acucela Inc. [ticker: 4589] 34
Acucela intends to aggressively protect and defend its intellectual
property position in Emixustat and VCM
• Strong patent portfolio is critical to our success
• Patents cover compositions of matter and methods of using the compositions
Major Press Coverage (Japanese)
• 東洋経済Online
アキュセラ、近く新たなパイプラインを発表、経営復帰から5カ月の窪田良CEOに聞く (2015年10月2日掲載)
• J-Wave 「JAM THE WORLD」ラジオ番組
「Breakthrough!」コーナーに窪田良が生出演。著書紹介、アキュセラの治療薬開発と挑戦を語る (2015年9月18日放送)
• ABCラジオ「おはようパーソナリティ道上洋三です」
「話のダイジェスト」コーナーに窪田良が生出演。起業の経緯、加齢黄斑変性、アキュセラの治療薬開発について語る(2015年9月17日放送)
• 日経ビジネスONLINE
キーパーソンに聞く 「革新は“プロ経営者”より研究者の情熱が生む」(2015年9月7日掲載)
• 日経バイオテク
米Acucela社の第2四半期決算説明会、フェーズIIb/IIIで約250人の被験者の投薬終了 (2015年8月29日掲載)
• 朝日新聞
(あの人とこんな話) 成長には痛みが伴うが筋トレ同様、鍛えられる (2014年4月15日掲載)
• 日経新聞
「重い目の病に飲み薬」東証単独上場初の米企業に (2014年3月25日掲載)
• 週刊ダイヤモンド
米国で起業しマザーズ上場 目のアルツハイマーを治す (2014年2月24日掲載)
• TBS 「夢の扉+」ドキュメンタリー
世界の1億2000万人を“失明の危機”から救え! 日本人トップイノベーターが挑む “不治の病”の治療薬開発 (2013年10月27日放送)
• ウォール・ストリート・ジャーナル
世界を変える日本人―シアトルで起業した窪田良氏が挑む難病治療薬(2013年3月29日掲載)
• PRESIDENT Online
<経営者の言葉:アキュセラCEO・窪田良>開眼!「朝令暮改」仕事術 (連載中)
その他メディア掲載については、当社ウェブサイトをご参照ください:wwww.acucela.jp
Acucela Inc. [ticker: 4589] 35
Acucela is a clinical-stage biotechnology
company that specializes in discovering and
developing novel therapeutics to treat and
slow the progression of sight-threatening
ophthalmic diseases affecting millions of
individuals worldwide.